2026年4月开始在香港、菲律宾和新加坡进行多重癌症血液测试。 Manulife and Guardant Health will launch a multi-cancer blood test in Hong Kong, the Philippines, and Singapore starting April 2026.

曼努利夫与护卫健康合作,从2026年4月开始在香港,菲律宾和新加坡推出"盾牌多种癌症检测测试",这是亚洲首个基于血液的测试. Manulife has partnered with Guardant Health to launch the Shield Multi-Cancer Detection test in Hong Kong, the Philippines, and Singapore starting April 2026, making it the first availability of the blood-based test in Asia. 该试验以平均风险为对象,以45岁及45岁以上者为对象,并持有美国食品及药物管理局的 " 突破装置 " 标识,通过抽血检测出10种常见癌症。 The test, which detects 10 common cancers with one blood draw, is aimed at individuals aged 45 and older at average risk and holds U.S. FDA Breakthrough Device Designation. 这项举措支持积极主动的保健管理,并在新加坡现有协作的基础上,扩大服务不足的亚洲社区获得预防性护理的机会。 The move supports proactive health management and expands access to preventive care in underserved Asian communities, building on existing collaboration in Singapore.